# Precirix

Source: https://onco.cc/companies/precirix/  
OnCo record `precirix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Precirix, of Brussels, develops radiopharmaceuticals built on small single-domain antibody fragments that carry a radioactive isotope to HER2-positive cancers. Its lead, CAM-H2, is in a phase 1/2 trial in HER2-positive breast, gastric and gastro-oesophageal cancer, including patients with brain metastases, with an imaging dose given first to confirm HER2 in the lesions.

## Summary

Precirix is a clinical-stage Brussels biotechnology company developing precision radiopharmaceuticals in oncology based on single-domain antibody (sdAb) targeting. Its lead candidate CAM-H2 is a HER2-directed radiopharmaceutical in a phase 1/2 trial, initially in Canada, evaluating safety, tolerability and efficacy in HER2-positive metastatic breast, gastric and gastro-oesophageal cancer, including patients with brain metastases. Patients first receive an imaging dose to confirm HER2 expression in lesions before therapeutic dosing. In June 2023 Precirix announced production of a first clinical trial batch of CAM-H2 at Evergreen Theragnostics in New Jersey to support expansion of the trial to the United States.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Brussels
- Type: radiopharma
- Website: https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/

## Notes

- Financing (a EUR 80 million Series B reported by Fierce Biotech, whose page returned HTTP 403) is omitted as unsourced. Current operating status is uncertain given the offline website.

## Sources

- Official website: https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [HER2](https://onco.cc/targets/her2/)

---
JSON: https://onco.cc/api/v1/entities/precirix.json